FRMM — Forum Markets, Share News
0.000.00%
Last trade - 00:00- $74.02m
- $34.32m
- $6.55m
U.S. STOCKS ON THE MOVE-Tesla, Netflix, Entrada Therapeutics, Gilead Sciences
U.S. STOCKS ON THE MOVE-Tesla, Madrigal, Walt Disney
Brief: 180 Life Sciences Announces 1-For 20 Reverse Stock Split As Part Of Nasdaq Compliance Plan
Brief: 180 Life Sciences Provides Update On Progress To Seek Authorization For Anti-TNF Treatment Of Early Stage Dupuytren's Contracture
U.S. STOCKS ON THE MOVE-Spectrum Pharma, Activision Blizzard
Brief: 180 Life Sciences Corp Received Written Notice From Nasdaq For Not Being In Compliance With Minimum Bid Price Requirement
Brief: 180 Life Sciences Corp Scheduled Meeting During Q4 2022 With MHRA Regarding its Phase 2B Data In Dupuytren’S Disease
Brief: 180 Life Sciences With The University Of Oxford Announce Enrollment Of First Patient In A Trial Of Anti-TNF For People With Early-Stage Frozen Shoulder
Brief: 180 Life Sciences Announces $6.5 Million Registered Direct Offering
U.S. STOCKS ON THE MOVE-Boeing, 180 Life Sciences, VectivBio Holding
U.S. STOCKS ON THE MOVE-Waterdrop, 180 Life Sciences, Tapestry
U.S. STOCKS ON THE MOVE-Tapestry, Waterdrop, 180 Life Sciences
180 Life Sciences slides on regulatory responses for hand deformity therapy
Brief: 180 Life Sciences Provides Update On Correspondence Received From U.K. And U.S. Regulatory Authorities On Pathway For A Therapy That Could Prevent Progression Of Early-Stage Dupuytren's Disease
Brief: 180 Life Sciences Corp Files For Mixed Shelf Of Up To $125 Million
Brief: 180 Life Sciences Begins Consultations With UK And U.S. Regulatory Authorities On Pathway For A Therapy That Could Prevent Progression Of Early-Stage Dupuytren’S Disease
Brief: 180 Life Sciences Corp Files Prospectus Related To Proposed Resale Of 4.8 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: 180 Life Sciences And University Of Oxford Announce Publication Of Positive Phase 2B Dupuytren's Disease Study Results In Lancet Rheumatology
Brief: 180 Life Sciences Says FDA Declined To Grant Meeting About Prelim Discussion For Dupuytren's Disease Treatment